Potential Treatment for Levodopa-Induced Dyskinesia Under Review

Three placebo controlled trials showed efficacy in Parkinson's disease patients with LID
Three placebo controlled trials showed efficacy in Parkinson's disease patients with LID

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ADS-5102 (amantadine extended-release capsules; Adamas) for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.

The NDA submission was based on data from three placebo-controlled trials, EASED, EASE LID and EASE LID 3, which evaluated the safety and efficacy of ADS-5102 in Parkinson's disease patients with LID. Results showed that patients treated with ADS-5102 demonstrated a primary reduction of LID and a secondary reduction in OFF time, as well as, a manageable and tolerable safety profile. In addition, data from an ongoing safety trial, EASE LID 2, also supported the NDA. 

Related Articles

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 24, 2017 to make a decision on the NDA. If approved, ADS-5102 will become the first and only drug therapy for Parkinson's disease patients with LID.

ADS-5102 is a chrono-synchronous amantadine therapy administered once daily at bedtime to time the delivery of amantadine drug levels to waking hours when LID episodes are most frequent.

For more information visit Adamaspharma.com.